Crossmark

Impact of the therapeutic positioning report in the P&R process in Spain: analysis of orphan drugs approved by the European Commission and reimbursed in Spain from 2003 to 2019

Crossref DOI link: https://doi.org/10.1186/s13023-020-01507-4

Published Online: 2020-08-28

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Badia, Xavier https://orcid.org/0000-0001-7568-2550
Vico, Tania

Shepherd, John

Gil, Alicia

Poveda-Andrés, José Luis

Hernández, César
License Information

Text and Data Mining valid from 2020-08-28

Version of Record valid from 2020-08-28
More Information

Article History

Received: 31 March 2020

Accepted: 9 August 2020

First Online: 28 August 2020

Ethics approval and consent to participate

: Not applicable. The study did not involve human participants (patients or otherwise). In 2017, Omakase Consulting S.L. developed an OD database to collect data related to medicinal products with OD designation, currently authorised in Europe and their P&R situation in Spain. The study was conducted by analysing data from the mentioned database. The study does not require ethics approval or otherwise approval since it does not involve the participation of patients or the enquiry/analysis of medical records.

: Not applicable. The study did not contain data from any individual person.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below